Your Fastest Path to Rare Disease Patients, Data, and China Early Access
We connect rare disease data, real-world evidence, and early access infrastructure to help global biotech accelerate development and market entry.
30+ million
Rare-Disease Data Points Connected
Across genomics, registries, natural history studies, and real-world evidence, G-Plume connects large-scale, structured rare-disease data assets to support early research, evidence generation, and development decision-making.
500k
Rare-Disease Families in Registries
Through strategic data partnerships, G-Plume enables access to one of the world’s largest rare-disease family datasets, supporting precise patient identification, stratification, and long-term follow-up.
200+
Clinical & Research Partners Worldwide
G-Plume collaborates with hospitals, research institutes, advocacy organizations, and ecosystem partners across regions, forming an integrated network for clinical execution and evidence development.
Our Core Strategic Partners
MyGenostics — The Foundation of Data
Core Value:
G-Plume is MyGenostics’ exclusive strategic partner for product development strategy. Leveraging China’s largest rare disease genetic database—covering 600,000+ families and a network of 500+ hospitals—we can precisely identify eligible patients and significantly shorten clinical enrollment timelines.
Industrial Park Partnerships – Accelerating China Market Entry
Core Value:
G-Plume partners with leading life-science industrial parks in China to help rare disease and innovative therapies enter the Chinese market faster and more effectively.
By leveraging industrial parks as integrated policy and execution hubs, we enable sponsors to: Navigate cross-border drug import and local policy coordination Access accelerated pathways for rare disease and urgent clinical need therapies Convert policy support into real patient access and on-the-ground execution
Boao Life Health Hospital
Core Value:
A Lecheng-based specialty hospital focused on rare diseases and longevity medicine. By leveraging China’s only medical special-zone policies, the hospital supports early clinical application and real-world insight generation, enabling overseas innovators to accelerate China entry and patient access in collaboration with G-Plume
Aplus Consultant — The Engine of Global Expansion
Core Value:
As G-Plume’s global strategic advisor, Aplus provides strong cross-border commercial and regulatory capabilities. From guiding U.S. biotech companies through China market access strategies to supporting Chinese innovators in applying for FDA Orphan Drug Designation (ODD), Aplus ensures every G-Plume project aligns precisely with global standards.
⭐⭐⭐⭐⭐
“In rare disease development, finding patients and meeting strict regulatory requirements are the biggest challenges. G-Plume precisely identified our target population through the MyGenostics genetic database and shortened our time to market by at least 18 months using the Hainan RWE pathway. They are not just a CRO—they are a powerful resource accelerator.”
Chief Clinical Officer, Boston-based Gene Therapy Company
Closing Thought
If orphan drug development is a climb across steep peaks, G-Plume is your experienced lead guide. Our partners act as the radar station forecasting conditions (research institutes), the logistics base ensuring supplies (super hospitals), and the intelligent navigation system identifying the shortest route (Healx). With this united team, even the most challenging summit is within reach.
